GoldenGolden
Advanced Search
Dementia Discovery Fund

Dementia Discovery Fund

Dimentia Discovery Fund is specialist venture capital fund investing in sciences that promote the creation of new medicines

Dementia Discovery Fund is specialist venture capital fund investing in sciences that promote the creation of new medicines. The firm was founded in 2015 in London, England, United Kingdom.

The fund is the largest firm that is focused entirely on developing therapies for dementia and Alzheimer's disease. Dementia Discovery Fund is interested in companies that provide platforms for therapeutics, medicines for astrocytes, biotechnology, antibodies and neuroimmunology, and monoclonal microbials. The firm is comfortable being a lead investor.

Timeline

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Transine Therapeutics
June 2, 2021
www.prnewswire.com:443
/PRNewswire/ -- Transine Therapeutics ('Transine'), a biotechnology company developing a novel class of therapeutic RNAs based on its pioneering SINEUP®...
FinSMEs
May 10, 2021
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
Cumulus Neuroscience
May 4, 2021
www.prnewswire.com:443
/PRNewswire/ -- Cumulus Neuroscience (Cumulus, The Company), formerly known as BrainWaveBank, announces a £6m financing round led by the Dementia Discovery...
Mark Terry
April 15, 2021
BioSpace
Several companies launched with Series A financing rounds today. Read on for details.
April 15, 2021
BioSpace
Alchemab raises £60M ($82M) in Series A financing to advance novel platform for identifying disease-modifying antibody therapeutics - read this article along with other careers information, tips and advice on BioSpace

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.